Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q4 2018 (← Previous) (Next →)

Filing Date: Feb 13, 2019

Total Value: $2.048B (100.0% shares, 0.0% debt)

Holdings (7)

MRNA MODERNA INC 43.9%

Value $898M Shares 58,807,379 Est. Cost $16.43 Unrealized 0.0%

— RUBIUS THERAPEUTICS INC 30.1%

Value $616M Shares 38,296,526 Est. Cost $24.00 Unrealized —

— EVELO BIOSCIENCES INC 11.6%

Value $237M Shares 18,233,403 Est. Cost $11.80 Unrealized —

DNLI DENALI THERAPEUTICS INC 9.0%

Value $184M Shares 8,918,749 Est. Cost $17.97 Unrealized +0.9%

— SERES THERAPEUTICS INC 2.8%

Value $57.33M Shares 12,682,876 Est. Cost $12.29 Unrealized —

QTRX QUANTERIX CORP 1.8%

Value $37.18M Shares 2,030,495 Est. Cost $19.52 Unrealized -8.1%

— SYROS PHARMACEUTICALS INC 0.9%

Value $17.85M Shares 3,204,437 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	MODERNA INC	58,807,379	$898M	43.9%	$16.43	0.0%	COM	60770K107
—	RUBIUS THERAPEUTICS INC	38,296,526	$616M	30.1%	$24.00	—	COM	78116T103
—	EVELO BIOSCIENCES INC	18,233,403	$237M	11.6%	$11.80	—	COM	299734103
DNLI	DENALI THERAPEUTICS INC	8,918,749	$184M	9.0%	$17.97	+0.9%	COM	24823R105
—	SERES THERAPEUTICS INC	12,682,876	$57.33M	2.8%	$12.29	—	COM	81750R102
QTRX	QUANTERIX CORP	2,030,495	$37.18M	1.8%	$19.52	-8.1%	COM	74766Q101
—	SYROS PHARMACEUTICALS INC	3,204,437	$17.85M	0.9%	$13.87	—	COM	87184Q107